ESC ranking puts AstraZeneca's Brilinta ahead of Lilly's Effient and clopidogrel
This article was originally published in Scrip
Executive Summary
The European Society of Cardiology has backed the use of AstraZeneca's new oral antiplatelet agent ticagrelor (Brilinta/Brilique), giving it its highest class 1 recommendation in its latest guidelines for the treatment of ST-elevation acute myocardial infarction (STEMI).